Oracle’s 26% Slide Hides a $638 Billion Compounding Machine
Oracle shares are down 26% this year, yet the company’s forward-looking numbers tell a starkly different story than the stock price suggests. Its Remaining Performance Obligations — contracted revenue not yet recognized — hit a record $638 billion in the most recent quarter, while cloud revenue grew 47% year-over-year and Infrastructure-as-a-Service nearly doubled, up 93%. For patient investors, that gap between sentiment and substance is exactly the kind of setup worth studying.
The market’s skepticism centers on Oracle’s aggressive AI capital spending, with capex running near $35 billion this year to build out data center capacity. Wall Street has punished the stock for the spend, treating it as a drag rather than an investment. But Mizuho analyst Siti Panigrahi, who added Oracle to the firm’s August top-picks list, argues the buildout is the fuel for a structural inflection: he projects 34% operating income compound annual growth through fiscal 2030, more than ten times the 3% CAGR Oracle delivered between 2010 and 2020. That’s not incremental improvement — it’s a business model shift, powered by database, infrastructure, and application layers all monetizing the same AI wave simultaneously.
What makes this interesting for value-oriented investors isn’t just the growth math — it’s the valuation mismatch it creates. A company compounding operating income at more than 10x its historical rate, with backlog visibility stretching years into the future, is trading at a discount most investors reserve for businesses in decline, not businesses accelerating. Oracle’s transformation from a legacy database vendor into critical AI infrastructure plumbing — sitting underneath enterprise workloads that are expensive and disruptive to migrate away from — is exactly the kind of durable, moat-widening shift long-term holders should want to own before consensus catches up.
So what for long-term investors: backlog conversion, not quarterly headlines, is the metric to track here. If Oracle converts even a fraction of that $638 billion RPO into recognized revenue at improving margins over the next several years, today’s 26% drawdown may look, in hindsight, like the entry point patient capital was waiting for.
